Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies
- 22 February 2011
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 108 (10), 4141-4146
- https://doi.org/10.1073/pnas.1011037108
Abstract
Histone deacetylase inhibitors (HDACi) have been successfully used as monotherapies for the treatment of hematological malignancies; however, the single agent effects of HDACi against solid tumors are less robust. Using preclinical models of lymphoma, we have recently demonstrated that HDACi induce tumor cell-specific apoptosis and that this is essential for the therapeutic effects of these agents. Herein, we demonstrate that HDACi can be combined with immune-activating antibodies designed to promote the function of antigen-presenting cells (APCs) and enhance proliferation and survival of cytotoxic T cells (CTL) to stimulate a host antitumor immune response resulting in eradication of established solid tumors. This unique combination therapy was dependent on tumor cell apoptosis mediated by HDACi that stimulated the uptake of dead tumor cells by APCs. Tumor eradication was mediated by CD8+ CTL that used perforin as the key immune effector molecule. This combination therapy was well tolerated and induced long-term immunological antitumor memory capable of mediating spontaneous tumor eradication upon rechallenge. These studies indicate that the ability of HDACi to mediate subtherapeutic levels of tumor cell apoptosis can be exploited by combining with antibodies that augment host antitumor immune responses to mediate robust and prolonged eradication of solid tumors.Keywords
This publication has 45 references indexed in Scilit:
- Chemotherapy and radiotherapy: Cryptic anticancer vaccinesSeminars in Immunology, 2010
- Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer ImmunityCancer Research, 2010
- Rational Combinations Using HDAC InhibitorsClinical Cancer Research, 2009
- Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonistProceedings of the National Academy of Sciences of the United States of America, 2008
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cellsCancer Immunology, Immunotherapy, 2007
- Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen‐processing machinery components in a murine model for human papilloma virus 16‐associated tumoursImmunology, 2007
- Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphomaProceedings of the National Academy of Sciences of the United States of America, 2007
- Immune surveillance of tumorsJCI Insight, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006